InvestorsObserver
×
News Home

Is Indaptus Therapeutics Inc (INDP) a Stock to Watch After Losing -2.04% This Week?

Tuesday, May 24, 2022 10:44 AM | InvestorsObserver Analysts

Mentioned in this article

Is Indaptus Therapeutics Inc (INDP) a Stock to Watch After Losing -2.04% This Week?

The market has been neutral on Indaptus Therapeutics Inc (INDP) stock recently. INDP gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Indaptus Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on INDP!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With INDP Stock Today?

Indaptus Therapeutics Inc (INDP) stock is trading at $2.40 as of 10:40 AM on Tuesday, May 24, a loss of -$0.24, or -9.09% from the previous closing price of $2.64. The stock has traded between $2.38 and $2.55 so far today. Volume today is less active than usual. So far 83,915 shares have traded compared to average volume of 928,484 shares. To screen for more stocks like Indaptus Therapeutics Inc click here.

More About Indaptus Therapeutics Inc

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models. Click Here to get the full Stock Report for Indaptus Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App